BioWorld

July 8, 2008

View Archived Issues

Putative Cancer Promoter Might be Tumor Suppressor

Read More

DOE Spinout Aims to Harness Nell1 for Cardio Therapies

Read More

Other News To Note

Read More

Clinic Roundup

Read More

Agios Will Use $33M Series A to Target Cancer Metabolism

Agios Pharmaceuticals said it plans to use the proceeds from a just-completed $33 million Series A financing to establish a product and biology platform focused on a new class of drugs that regulate cancer metabolism. (BioWorld Today) Read More

Michigan Fund Uses $50M Pot to Woo Biotechs to Kalamazoo

Read More